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Abstract.  To investigate the functional significance of 
putative integrin divalent cation binding sites, several 
mutated 0/4 subunit cDNAs were constructed. Mutants 
contained the conservative substitution of Glu for Asp 
or Asn at the third position in each of three putative 
divalent cation sites. Transfection of wild-type or mu- 
tated ~  into K562 cells yielded comparable expres- 
sion levels and immunoprecipitation profiles.  However, 
for all three ~  mutants, adhesion to CS1/fibronectin 
was greatly diminished in either the presence or ab- 
sence of the stimulatory anti-ill mAb TS2/16.  Consti- 
tutive adhesion to vascular cell adhesion molecule 
(VCAM)  1 was also diminished but, unlike CS1  adhe- 
sion, was restored upon TS2/16 stimulation. In con- 
trast,  adhesion to the bacterial protein invasin was 
minimally affected by any of the three mutations. For 
each of the mutants, the order of preference for diva- 
lent cations was unchanged compared to wild-type O/4, 
on CS1/fibronectin (Mn  2÷ >  Mg  2÷ >  Ca2÷), on VCAM-1 
(Mn  2÷ >  Mg  2÷  =  Ca  2÷) and on invasin (Mg  2÷  =  Ca2÷). 
However for the three mutants, the efficiency of diva- 
lent cation utilization was decreased. On VCAM-1, 
68-108/zM  Mn  2÷ was required to support half- 
maximal adhesion for the mutants compared with 
14-18/~M  for wild-type 0/4. These results indicate (a) 
that three different ligands for VLA-4 show widely 
differing sensitivities to mutations within putative 
divalent cation sites, and (b) each of the three putative 
divalent cation sites in ~  have comparable functional 
importance with respect to both divalent cation usage 
and cell adhesion. 
N 
EARLY all integrin ligand binding activities are com- 
pletely inhibited by EDTA, but can be restored by 
the  addition of divalent cations.  Each  integrin el 
subunit has three or four putative divalent cation sites (24, 
36, 74) that partly resemble the EF-hand consensus structure 
seen  in  other  divalent  cation  binding  proteins  such  as 
calmodulin, troponin c, and paravalbumin (68).  From the 
studies of calmodulin and troponin C, an EF-hand is a loop 
structure in which acidic amino acids (Asp or Glu), together 
with other oxygen containing amino acids (at positions 1, 3, 
5, 7, 9,  12), provide 6 or 7 coordination sites for a divalent 
cation  (68).  Conservative mutations,  or  alanine  substitu- 
tions, at positions 1, 3, and 12 within troponin C EF-hands 
emphasize that those residues are critical for both function 
and cation binding (5,  53).  In another study, conservative 
mutations at position 9 of the EF-hand of the Escherichia 
Coli D-glucose and D-galactose receptor caused a change in 
both cation selectivity and affinity (16). 
Each of the three putative divalent cation sites of the inte- 
grin ~  subunit has the amino acid sequence Asp-X-Asp(or 
Asn)-X-Asp(or  Asn)-Gly-X-X-Asp  (Table  I),  which partly 
resembles the EF-hand motif (25,  69,  70).  These sites are 
likely to  be  important  for  integrin  function because  (a) 
ligand binding has been mapped to that region (9, 63),  (b) 
~3-4 cations were found to bind to a single integrin (64), 
(c) a synthetic peptide derived from a putative cation binding 
site inhibited ligand binding activity in a calcium-dependent 
manner (10), (d) divalent cations directly bound to a recom- 
binant fragment of o/lib containing putative cation sites (23), 
and (e) a mutation (Asp to Glu) at EF-hand position 5 abol- 
ished the fibrinogen binding activity of an  11-amino acid 
peptide spanning divalent cation site II of integrin 0/~ (10). 
Furthermore there are several examples of divalent cations 
having an impact on activation-specific integrin epitopes (11, 
20, 77), and also different divalent cations (eg., Ca  2÷, Mg  2÷, 
Mn  2÷) can dramatically alter the specificity of ligand bind- 
ing (14, 21,  36).  The putative divalent cation sites within 
integrins lack an acidic residue at EF-hand position 12, that 
is critical for cation coordination in other molecules (68, 74). 
Thus it has been hypothesized that the missing coordination 
residue might be supplied by integrin ligands (7, 74), which 
often contain aspartic acid at a critical position (3, 38, 39, 
52, 66, 78). However, despite these results and speculations, 
direct evidence has not yet been provided for a functional 
role of putative 0/subunit divalent cation binding sites in the 
context of an intact integrin heterodimer. 
The integrin VLA-4 is expressed on circulating blood cells 
(e.g.,  lymphocytes, monocytes, and eosinophils),  thymic 
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Domain  Residue number  Amino acid sequence 
123456789 
I  281-289  D  L  NADG  FSI3 
II  344-352  D  I  DN  DG  F  E_D 
IH  406-414  D A  D N N G Y V  D 
and bone marrow progenitors (75),  fetal myoblasts (57), 
some melanoma ceils  (54),  and several other cell types. 
Ligands for VLA-4 include vascular cell adhesion molecule 
(VCAM)M, a molecule expressed on activated endothelium 
(2, 13, 31, 34, 51, 55, 61), and the alternatively spliced cell 
attachment  domain,  CS1, within  the  Hep  II  region  of 
fibronectin (19, 22, 79). The VLA-4/VCAM-1  interaction is 
important for hematopoiesis (47, 59, 72),  fetal myogenesis 
(54)  and also may play a  critical role in the migration of 
mononuclear leukocytes to inflammatory sites (34)  and in 
the pathogenesis of diseases such as arthritis (40,  48,  76), 
atherosclerosis (8), and autoimmune encephalomyelitis (81). 
The VLA-4/CS1  interaction may be important during em- 
bryogenesis (12), bone marrow and thymic progenitor cell 
maturation (56, 72, 75, 80), and localization of sensitized T 
lymphocytes to antigenic sites (17). Like VLA-4 (an a4/31 
heterodimer), the od/37 heterodimer has also been found to 
mediate adhesion to VCAM-1 and to fibronectin (6, 58). 
Several integrins, including VLA-4, interact with invasin, 
an outer membrane protein from Yersinia  pseudotuberculo- 
sis that mediates bacterial penetration into mammalian cells 
(33). Surprisingly, VLA-4 on lymphocytes  had a high consti- 
tutive activity for adhesion to invasin (15), whereas adhesion 
to VCAM-1 and CS1/fibronectin is markedly more dependent 
on functional activation of the integrin (4, 45, 62, 78). 
As with other integrins, VLA-4-mediated adhesive func- 
tions  require  divalent cations.  The  function of VLA-4 is 
moderately supported by Mg  2+, enhanced in the presence of 
Mn  2+, and sometimes partially suppressed in the presence 
of Ca  2÷ (45).  Notably, the presence of Ca  2+ suppressed the 
function of  partly active but not fully active VLA-4, and sup- 
pressed adhesion to CS1/fibronectin but not VCAM-1 (45). 
These results point out not only a critical mechanistic differ- 
ence between VCAM-1 and CS1 as VLA-4 ligands, but also 
suggest that variations within divalent cation sites have a piv- 
otal role in the manifestation of different states of constitu- 
tive activity. 
A homology modeling study has demonstrated that a puta- 
tive divalent cation site from the integrin ct  4 subunit might 
use positions 1, 3, 5, 7, and 9 to form a structure similar to 
conventional EF-hands (74).  To directly explore the func- 
tional importance of  putative divalent cation sites for VLA-4 
in particular, and for integrins in general, we have mutated 
key residues within three different sites in the od subunit 
and stably expressed these constructs in K562 cells. These 
transfectants were then used to carry out a detailed analysis 
of VLA-4 adhesion to CS1/fibronectin, VCAM-1, and inva- 
sin. Remarkably, we found that divalent cation site mutagen- 
esis had a different influence on cell adhesion to each ligand. 
Also we found that each divalent cation site appeared to con- 
tribute comparably towards integrin function. 
1. Abbreviations  used in this paper: HBSA, heat-denatured BSA; MBP, mal- 
tose binding protein; VCAM, vascular cell adhesion molecule. 
Antibodies and Other Proteins and Reagents 
Monoclonal antibodies used  were as  follows:  anti-VLA-1,  TS2/7  (28); 
anti-VLA-2, 5E8 (83); anfi-VLA-3, J143 (18); anti-VLA-4, B-5G10  (30), 
HP1/7  (60), HPI/2 (60), L25 (46); anti-VLA-5, mAb 16 (1); anti-VLA-6, 
BQ16 (a gift from Dr. M. Liebert, University of  Michigan, Ann Arbor, MI); 
anti-VLA-/31, A-1A5 (27), TS2/16 (28); and the negative control antibodies 
P3 (35)  and J-2A2 (26). 
Recombinant soluble VCAM-I (rsVCAM-1) (42), and CS1 peptide con- 
jugated with BSA (CS1-BSA) were gifts from Dr. R. Lobb (Biogen Co., 
Cambridge, MA) and Dr. T. Shimo-Oka (Iwaki Glass Co., Tokyo, Japan), 
respectively. Coupling was carded out using the sulfo-MBS reagent (37), 
acting on a cysteine added to the amino-terminal end of the CSI peptide. 
An invasin-MBP (maltose binding protein) fusion protein containing the 
carboxy-termina1479  amino acids of invasin (41) was obtained from Dr. R. R. 
Isberg (Tufts  University, Boston, MA). Human fibronectin was obtained 
from Telios Pharmaceuticals (La Jolla, CA). 
Site-directed Mutagenesis and Transfections 
Full-length a 4 eDNA  in  Bluescript (70)  was  subjected to  site-directed 
mutagenesis using the Muta-Gane phagemid in vitro mutagenesis kit (Bio- 
Red,  Richmond,  CA),  as  recommended.  Oligonucleotides representing 
bases 976-1002 (for Asn  2s3 to Gln or Glu mutation), 986-1003 (for Asp2S5 
to Glu mutation), 1170-1187  (for Asp346 to Glu mutation), and 1355-1371 
(for Asp  4°s to Glu mutation) were used as primers. Base substitutions at 
sites of mutation were confirmed by DNA sequencing (82). Mutated ot  4 in- 
serts were then excised and ligated into the pFNeo expression vector, as pre- 
viously described (13). K562 cells were maintained in RPMI 1640 medium 
supplemented with 10%  FBS, L-glutamine and antibiotics (complete me- 
dia). 7.5  x  106 K562 cells were electroporated with 25/zg of the different 
pFNeo-a  4 constructs, and 48  h  after transfection, cells were placed in 
complete media containing 1.5 mg/ml of geneticin (G-418  sulfate; GIBCO 
BRL, Gaithersburg, MD). Ganeticin-resistant cells were analyzed by flow 
cytometry for VLA-4 surface expression using a FACScan machine, as pre- 
viously described (13),  and enriched by selection with immunomagnetic 
beads when necessary. 
The control cell line, 4RL, is derived from K562 cells transfected with 
~x  4 in  which the  80/70  cleavage site was abolished due  to  mutation of 
Arg  558 to Leu (73). 
Immunoprecipitation 
Cells were surface labeled with t25I using lactoperoxidase and lysed in the 
presence  of  1.0%  Triton  X-100.  Immunoprecipitation  and  SDS-PAGE 
analyses (on 7 % polyacrylamide gels) were carried out as previously de- 
scribed (29). 
Cell Adhesion Assays 
Cell attachment to ligand proteins was carried out in the presence or ab- 
sence of stimulatory or blocking antibodies as previously described (6, 45). 
Briefly,  cells were labeled by incubation with the fluorescent dye BCECF 
(Molecular Probes, Inc., Eugene, OR) and then 5  x  104 cells were added 
to 96-well microtiter plates (Flow Labs, Inc., McLean, VA) that had been 
coated with protein ligands and blocked with 0.1%  heat-denatured BSA 
(HBSA). After 20-25 rain of incubation at 37°C, unbound cells were re- 
moved by washing. Then, cells remaining attached to the plate were ana- 
lyzed using a  Fluorescence Concentration Analyzer machine (Millipore 
Corp., Bedford, MA). After subtraction of background cell binding, values 
for cells bound/mm  2 were calculated. Background cell binding (typically 
<2%) was assessed using BSA-coated wells in the experiments for CSI or 
for VCAM-1, and using MBP-coated wells in the experiments for invasin- 
MBP fusion protein. RPMI media (containing 0.5 mM Ca  2+ and 0.5 mM 
Mg  2+) was used as an assay buffer unless otherwise indicated. Results arc 
reported as the mean with the standard deviation of triplicate determina- 
tions. As previously shown (45)  adhesion of a4-transfected cells to CS1- 
BSA or to the FN33/66  fragments of fibronectin was nearly identical in 
terms  of  cation  dependence and  maximal  adhesion  supported.  Thus, 
CS1-BSA was used for most experiments due to its greater availability. 
The mAbs TS2/16, HP1/2,  and mAb 16 were added at a final concentra- 
tion of 3.0, 1.0, and 1.0/~g/ml, respectively. To analyze the effects of divalent 
cations, cells were washed with 1 mM EDTA in PBS after labeling with 
BCECE then washed once with TBS, and resuspended in TB8 containing 
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Mutants 
Domain  Position  Residue number  Mutation 
Results of transfection 
Expression  Stability 
I  3  283  N ~  Q 
I  3  283  N ~  E 
I  5  285  D --'-  E 
II  3  346  D ~  E 
III  3  408  D ~  E 
+ +  stable (N283E) 
+  unstable 
+ +  stable (D346E) 
+ +  stable (D408E) 
0.1%  HBSA and 2 mM glucose. CaC12, MgC12, or MnCI2 were then added 
to the plated cells in each well, and TBS was used instead of RPMI in all 
subsequent procedures. 
Results 
Construction and Expression of Mutated ~ 
Five different conservative mutations in the putative divalent 
cation  sites of the  ~  subunit  were designed  to  minimize 
disruption of the association of ot~ subunits (Table II). Al- 
though transfection into K562 cells was done at least 4 or 5 
times for each mutant, one of the mutations (N283Q)  was 
not expressed at all, and another (D285E) was expressed at 
levels too low and too unstable for functional analysis. In 
contrast, substitution of Glu for Asp or Asn at the third posi- 
tion of each divalent cation site yielded mutant t~  4 for which 
stable transfectants could successfully be established. These 
transfectants, mutated in cation sites I, II, and III were desig- 
nated N283E,  D346E,  and D408E,  respectively, and were 
expressed  at  levels  comparable  to  wild-type  t~  in  K562 
cells  (called  KA4),  as  detected  by  intmunofluorescence 
m 
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Figure 1. Cell surface expression of VLA-4 heterodimers on trans- 
fected K562 cells. Transfected K562 cells stained with control mAb 
J-2A2 (dotted line) or anti-VLA-4 mAb B-5GI0 (solid line) were 
measured by flow cytometry. 
staining using VLA-4-specific mAb B-5G10 (Fig.  1, panels 
KA4,  N283E,  D346E,  and  D408E).  In  comparison,  the 
mock-transfected cell (KpF) expressed barely a trace level of 
(Fig.  1, panel KpF). Additional staining comparing three 
different  VLA-4-specific mAbs  (HP1/7,  HP1/2,  L25)  that 
define distinct epitopes of a 4, yielded identical profiles for 
each transfectant (data not shown). Also, no marked altera- 
tions in the expression of endogenous VLA-5 were observed 
among the five transfectants used in this study,  and no ex- 
pression  of VLA-1,  -2,  -3,  or  -6  was  observed  (data  not 
shown). 
Analysis  of VLA-4  expression  by  inlmunoprecipitation 
using an anti-~ mAb yielded nearly identical patterns of 
and/31  proteins for each transfectant (Fig. 2, lanes b-e). In 
addition anti-~l mAB immunoprecipitated the/5~  subunit in 
association with both transfected ot  4 and the endogenously 
expressed a s from KA4 cells (Fig. 2, lane a) and from each 
mutant transfectant (not shown). 
Adhesion ofK562 Transfectants to CS1 and to VCAM-1 
Neither KA4 cells nor any of the mutants adhered to CS1 in 
the  absence of stimulation by the anti-/3~ antibody TS2/16 
(Fig. 3). In the presence of TS2/16, KA4 cells showed moderate 
adhesion,  whereas  N283E  cells and  D346E  cells adhered 
minimally to CS1,  and adhesion by D408E cells was at an 
intermediate level. A somewhat different result was observed 
for  adhesion  to  VCAM-1.  KA4  cells  readily  adhered  to 
VCAM-1, and this adhesion was amplified only 1.3-1.8  fold 
by TS2/16 (Fig. 4). In contrast, N283E cells and D346E cells 
(and to a lesser extent D408E cells) showed much less adhe- 
sion to VCAM-1  in the absence of stimulation, but TS2/16 
stimulation brought them up to a comparable level of adhe- 
sion as seen for KA4 cells. Adhesion of all of these ceils to 
CS1 or to VCAM-1 was entirely mediated by VLA-4 because 
the mock-transfected (KpF)  cells did  not adhere to either 
CS1  or VCAM-1,  regardless of TS2/16  stimulation. 
Figure  2.  Immunoprecipita- 
tion  of  VLA-4  from  trans- 
fected K562 cells.  Equivalent 
amounts  of  KA4,  N283E, 
D346E,  and  D408E  cells 
were  radiolabeled  with  ~25I, 
extracted  with  Triton  X-100, 
and then immunoprecipitated 
using either the anti-~l  mAb 
A-LA5 (lane a), or the anti-o? 
mAb B-5G10 (lanes b-e)~ The 
negative control  antibody  P3 
yielded blank lanes from each 
cell extract (not shown). 
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Figure 3. Adhesion of transfected  K562 cells to CS1 peptide.  Cells 
(KpF, KA4, N283E, D346E, and D408E) were tested for adhesion 
to microtiter plates coated with various amounts of CS1-BSA in the 
presence  or  absence  of TS2/16  as  described  in  Materials  and 
Methods. 
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Comparison of VLA-4-mediated Adhesion ofK562 
Transfectants to CS1, VCAM-I, and Invasin 
For invasin adhesion experiments,  plates were coated with 
low  levels  of invasin-MBP  fusion protein to  avoid VLA- 
4-independent  background  adhesion,  and  also  cells  were 
preincubated with anti-cd mAb  16 to block the slight con- 
Figure 5. Comparison of VLA-4-mediated adhesion of transfected 
K562 cells to its three ligands.  Cells (KpF, KA4, N283E, D346E, 
and D408E) were tested  for adhesion to microtiter plates  coated 
with 2.5/@/ml of CSI-BSA, 2.5 #g/ml of rsVCAM-1, or0.4/~g/ml 
of invasin-MBP fusion protein (INV-MBP) in the presence or ab- 
sence of TS2/16 as described in Materials  and Methods.  HP1/2 was 
added where indicated,  and cells were preincubated  with mAb 16 
for invasin experiments. 
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Figure 4.  Adhesion of transfected  K562 cells  to VCAM-1. Cells 
(KpF, KA4, N283E, D346E, and D408E) were tested for adhesion 
to microtiter plates  coated with various amounts  of rsVCAM-1 in 
the presence or absence of TS2/16 as described in Materials  and 
Methods. 
tribution of VLA-5 to adhesion.  Using these experimental 
conditions, cell adhesion was almost completely inhibited by 
the  anti-o¢  mAb  HP1/2  (Fig.  5  C)  thus  confirming  that 
VLA-4 plays a major role. In the absence of TS2/16 stimula- 
tion,  adhesion  of each  mutant  transfectant  to invasin  was 
only partially diminished,  down to a level that was 62-71% 
relative to that seen with KA4 cells.  With TS2/16 stimula- 
tion, adhesion by the mutants was 90-98%  relative to KA4 
cells. 
In comparison,  there  was  no  adhesion  to  CS1  without 
TS2/16  stimulation,  and  adhesion  of N283E,  D346E,  and 
D408E  cells  to  CS1  was  still  greatly  diminished  (8,  14, 
39 % relative to KA4 cells, respectively) when stimulated by 
TS2/16 (Fig. 5 A). Adhesion of N283E, D346E, and D408E 
cells to VCAM-1 was diminished (26,  15, and 34%, respec- 
tively, relative to KA4 cells) without TS2/16 stimulation, but 
upon TS2/16 stimulation was restored to 83, 68, and 83 %, 
respectively,  relative to KA4 cells  (Fig.  5 B). 
In conclusion, as the result of mutations  in the putative 
divalent  cation  sites  of cd,  VLA-4-mediated  adhesion  to 
CS1 was greatly diminished regardless of stimulation, adhe- 
sion to VCAM-1 was diminished but restored upon VLA-4 
stimulation, and adhesion to invasin was minimally affected. 
Effects of Divalent Cations on Adhesion 
To obtain optimal  conditions for analysis of the effects  of 
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Figure 6.  Effects  of Mg  2+ and  Ca  2+ on adhesion of transfected 
K562 cells to its three ligands. Cells (KpF, KA4, N283E, D346E, 
and D408E) were incubated  with TS2/16, and tested for adhesion 
to microtiter plates coated with 2.5/zg/ml of CS1-BSA,  2.5 #g/ml 
of rsVCAM-1, or 0.4 #g/ml of invasin-MBP fusion protein (INV- 
MBP) in the presence of 2.0 mM Mg  2÷ or 2.0 mM Ca  2÷ as de- 
scribed in Materials  and Methods.  Cells were preincubated  with 
mAb 16 for invasin experiments,  and mAb HPI/2 was added where 
indicated. 
divalent cations on adhesion, TS2/16 was included in all as- 
says (Figs. 6  and 7).  In the wild-type ~  transfectant (KA4 
cells), Ca  2÷ was much less effective than Mg  2÷ in supporting 
adhesion  to  CS1,  and  in  the  mutants,  Ca  2+  was  totally 
ineffective (Fig.  6 A). In contrast,  Ca  2÷ was as effective as 
Mg  2÷ in supporting adhesion to either VCAM-1 or to inva- 
sin (Fig. 6, B and C). Notably, these results obtained using 
saturating levels of Mg  2÷ or Ca  2÷ (2 mM) are comparable to 
the results obtained in Figs.  3-5 using RPMI media (Mg  2÷ 
and Ca  2÷ each at 0.5 mM). 
Although adhesion  in  the  presence  of 1 mM  Mn  2÷ was 
somewhat increased (Fig.  7  C) relative to adhesion in the 
presence of 2 mM Mg  2÷ (Fig. 7 A), the mutant transfectants 
were still markedly deficient in their ability to adhere to CS1. 
When  adhesion  to  fibronectin  was  analyzed,  the  mutants 
were similarly found to be deficient both in the presence of 
2 mM Mg  2÷ (Fig.  7 B) and in the presence of 1 mM Mn  2÷ 
(Fig. 7 D).  For these experiments,  cells were preincubated 
with the anti-a  5 mAb  16 to block VLA-5-mediated adhe- 
sion, and thus we were able to obtain cell adhesion that was 
almost completely inhibited by anti-od mAb HP1/2 (Fig.  7, 
B and D), indicating that the observed adhesion was largely 
VLA-4 mediated. 
When  adhesion  of VCAM-1  was  analyzed  over  a  wide 
range of Mn  :÷ concentrations (Fig.  8), the titration profiles 
for K562 cells containing N283E, D346E, and D408E muta- 
tions  were  similar,  each  showing  half-maximal  adhesion 
(ED50 values) at 55-85/~M  Mn  2÷. In contrast,  K562 cells 
containing wild-type t~' (KA4)  had an ED50 value of ap- 
proximately  10 #M,  and  K562  cells  (4RL)  containing  ed 
with an unrelated mutation (abolishing  the 80/70 cleavage 
site) (73) had a similar ED50 values (~12/~M).  From four 
different experiments such as shown in Fig. 8, average ED50 
values were obtained (Table III) showing that the efficiency 
of Mn  2+ utilization was altered 4-7-fold by mutations N283E, 
D346E,  and D408E. 
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Figure  7.  Comparison  between 
adhesion to CS1 and to fibronec- 
tin.  Cells  (KpE  KA4,  N283E, 
D346E,  and  D408E)  were  in- 
cubated with TS2/16, and tested 
for adhesion to microtiter plates 
coated  with  2.5  #g/ml  of CS1- 
BSA or 1.0 ttg/ml of fibronectin in 
the presence of 2.0 mM Mg  2÷ or 
1.0  mM  Mn~  +  as  described  in 
Materials  and Methods. The dose 
of  fibronectin  used  was  near 
saturating  with  respect  to  inte- 
grin-dependent adhesion. At high- 
er  doses  (not  shown),  non-in- 
tegrin  dependent  adhesion  was 
observed.  Cells  were  prein- 
cubated with mAb 16 for fibro- 
nectin  experiments,  and  HP1/2 
was added where indicated. 
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Figure 8. Effect of Mn  2÷ on cell adhesion to VCAM-1. Cells (KpF, 
KA4, 4RL, N2g3E, D346E, and D408E) were tested for adhesion 
to microtiter plates coated with 2.5/xg/ml  rsVCAM-1 in the pres- 
ence of the indicated concentrations of Mn  2÷, and in the absence 
of the antibody TS2/16, as described in Materials and Methods. 
In a  control experiment, ED50 values were determined 
for K562 cells expressing different levels of wild-type ot  4, 
varying over a  10-fold  range.  Although maximal adhesion 
varied with expression, ED50 values were comparable to 
those seen in Table UI (not shown). Thus, the ED50 values 
appear to be independent of the overall adhesive state of the 
cell. When adhesion assays were carried out using invasin in- 
stead of VCAM-1,  or Mg  2÷ instead of Mn  2÷, ED50 values 
were elevated by several fold for mutations N283E, D346E, 
and D408E (not shown), consistent with results in Table III. 
Discussion 
Contrasting Effects of Mutations on Adhesion 
to Different VLA-4 Ligands 
In this study, we have established that each of the three puta- 
tive divalent cation binding sites in the o~ subunit play criti- 
cal roles in determining VLA-4-mediated adhesive activity 
to its ligands.  Conservative mutation of these sites did not 
disturb heterodimer assembly with endogenous/3~, but did 
Table IlL  ED50/Mn  2+ for Each Transfectant 
in Adhesion to  VCAM-1 
Cell  ED50/Mn 2+ 
#M 
KA4  18  +  6 
4RL  14  +  6 
N283E  108  +  21¢ 
D346E  90  +  17~ 
D408E  68  +  14" 
Values of ED50/Mn 2÷ (50% maximal effective dose of Mn  2÷) in adhesion to 
VCAM-1 were determined as shown in Fig. 8. The results are the mean +  SE 
of four independent experiments done in triplicate.  Statistical differences from 
control  (KA4 cell) were determined by t test. 
*p <  0.05. 
~: p <  0.01. 
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Figure 9.  Schematic diagram 
depicting multiple  activation 
states of VLA-4. 
clearly affect ligand binding activity. Depending on which 
VLA-4 ligand was used in cell adhesion assays, these three 
mutations resulted in (a) nearly complete loss of function, 
(b) partial loss of function, or (c) minimal effect on function. 
The nearly complete loss of VLA-4-mediated adhesion to 
CS1/fibronectin could not be overcome by the addition of 
function-stimulating agents. Adhesion to VCAM-1 was also 
substantially diminished in all three mutants, but this effect 
could be overcome by the addition of the stimulatory anti- 
/31 antibody TS2/16. In contrast to the other ligands, the bac- 
terial protein invasin supported a high level of VLA-4-medi- 
ated adhesion that was not dependent on stimulatory agents, 
and was only minimally influenced by position 3 mutations. 
Together these results emphasize the versatility of a single 
integrin, VLA-4, able to interact in a distinct manner with 
three different ligands. 
Perhaps the simplest explanation for these results is that 
weaker interactions are more susceptible to partial disabling 
Of the ligand binding site thus causing them to drop below 
the threshold of the adhesion assay. Shown schematically in 
Fig. 9 are five arbitrary stages of VLA-4 activity. Wild-type 
VLA-4 in transfected K562 cells is at stage IN, and can be 
pushed up to stage IV or V upon the addition of TS2/16 or 
Mn  2÷. In contrast, mutated VLA-4 has been shifted to stage 
II, where interaction with invasin is retained, VCAM-1  is 
diminished, and CS1/FN is absent. Stimulation of  the mutated 
VLA-4 can restore stage III or IV activity, as adhesion to in- 
vasin is still maintained at a high level, VCAM-1 is somewhat 
restored,  and CS1/FN  is  still largely absent.  Even in the 
presence of both Mn  2÷ and TS2/16, the mutated VLA-4 could 
not reach stage V. These results confirm and extend previous 
results (45) showing that putative divalent cation sites are likely 
to play a critical role in determining the activation state of 
VLA-4. 
To develop this model further, direct ligand binding affinity 
measurements would be helpful. However, we have been un- 
able to obtain such measurements using fibronectin (or FN 
40 fragment), CS1 peptide, VCAM-1, or invasin because the 
interactions of the former with VLA-4 are too weak (espe- 
cially in  the  mutants),  because there is  a  large  integrin- 
independent binding component for CS1 and invasin, and be- 
cause sufficient VCAM-1 material is not available. At present 
we predict that invasin would have the highest affinity,  fol- 
lowed by VCAM-1, and then CS1/fibronectin. Consistent with 
this, the affinity of invasin for VLA-5 has been found to be 
two orders of magnitude higher than the affinity determined 
for VLA-5/fibronectin (50). 
Regardless of the precise affinity constants, it is clear that 
changing Asn or Asp to Glu in position 3 of each of the puta- 
tive divalent cation sites had a dramatic effect on adhesion, 
especially for weaker ligands such as CS1 or fibronectin, or 
VCAM-1 in the absence of integrin stimulation. We predict 
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as the Leu-Asp-Val tripeptide (78) would have an even higher 
threshold for activation, leading to a greater requirement for 
stimulation, and an even greater sensitivity to mutagenesis 
such as performed here. 
The effects of our mutations on VLA-4-dependent adhe- 
sion to intact fibronectin were very similar to the effects on 
adhesion to CS1 peptide. Thus, other regions within fibronec- 
tin reported to be involved in VLA-4-mediated adhesion (32, 
44, 49) either are functionally indistinguishable from the CS1 
region, or are not functioning in our assays. 
The constitutively high adhesion-supporting properties of 
invasin are in striking contrast to the other VLA-4 ligands, 
and consistent with previous suggestions that adhesion to in- 
vasin does not require cellular activation (15). This aspect of 
the invasin/VLA-4 interaction places invasin-bearing bacte- 
ria outside of the normal activation dependent constraints on 
other VLA-4 ligands, and thus may favor the spread of the 
bacteria.  We  have also  found that,  although  VLA-4  and 
VLA-5 are present in nearly equal amounts on ~-transfected 
K562 cells, the major contribution towards adhesion to inva- 
sin is provided by VLA-4. It remains to be determined why 
VLA-5 would be a very high affinity receptor for invasin in 
some studies (50), but relatively ineffective in ours and other 
(15) studies. One possibility is that fusion proteins contain- 
ing different portions of invasin (41) could have altered inte- 
grin specificities. 
Implications Regarding Divalent Cation Sites 
Conservative changes of Asp or Asn to Glu at position 3 
within sites I, II, and III were sufficient to allow VLA-4 ex- 
pression,  but alter adhesive function.  These conservative 
mutations did not appear to cause gross changes in the over- 
all  integrin  structure because  (a)  association between  od 
and/31 was retained, (b) three distinct tx  4 epitopes were un- 
altered, and (c) VLA-4-dependent adhesion to at least one 
ligand, invasin, was minimally affected. The observed func- 
tional alterations appeared to be specific for these mutations. 
For example, mutation of the a 4 80/70 cleavage site (73) 
had no effect on cell adhesion or cation utilization. Also, mu- 
tations of Cys  ~78 (three residues away from site I),  Cys  717, 
Cys  TM, and Cys  g28 had no effect on either cell adhesion or 
divalent  cation  utilization  (Pujades,  C.,  J.  Teixid6,  and 
M.  E. Hemler, unpublished observations). 
The most likely interpretation of the functional effects of 
the N283E, D346E, and D408E mutations is that the pres- 
ence of a larger amino acid (Glu) may have disrupted the ter- 
tiary structure at the cation binding site, and perhaps even 
prevented cation binding. In this regard, substitution of Glu 
for Asp in position 3 of a divalent cation site in troponin C 
yielded functionally inactive protein with concomitantly di- 
minished cation binding capacity (5, 53). 
Thus far, because we have elected to study putative diva- 
lent cation sites in the context of the intact VLA-4 heterodi- 
mer,  it  has  been  impractical  to  directly  determine  the 
stoichiometry of cation binding to the mutant integrins due 
to the very large amount of  protein required, and the instabil- 
ity of the purified VLA-4 heterodimer (31). 
Also, we have not yet been able to successfully express 
od in which more radical mutations have been carried out 
(e.g., Asp to Ala at positions 1, 3, 5, or 9), and even some 
conservative mutations have yielded unstable integrins. For 
example, we mutated position 5 (Asp to Glu) within o~  4 site 
I, but the resulting integrin was not sufficiently stable to al- 
low functional studies (Table II). Likewise, we were unable 
to express mutated ot  4 containing a conservative Asn to Gin 
mutation at position 3 within site I. These results emphasize 
that EF-hand residues not only may be important for integrin 
function, but also may play a role in heterodimer assembly 
and/or maturation. Thus, it appears that mutants which are 
expressed and also show functional alterations represent a 
narrow window between no expression and no functional 
effects. 
Mutations within Sites L II, and III Have 
Comparable Effects 
Regardless of whether cation binding is eliminated from site 
I, II, or HI, or merely altered, it is clear that the efficiency 
of  divalent cation utilization has been similarly decreased for 
each position 3 mutant, and at the same time adhesive func- 
tions have been similarly influenced. In some instances the 
effects of the mutation in site II were slightly more obvious, 
and the effects of the site HI mutation were a little less obvi- 
ous, but overall, the effects were comparable. 
Whereas all integrin ct chains have 3-4 putative divalent 
cation sites, the extent to which each one contributes has not 
been clear. The noncompetitive inhibition of Mg  2+ binding 
to VLA-2 by Ca  2+ has suggested distinct sites for different 
cations (65). Other studies have found that a nb cation bind- 
ing sites may be heterogeneous with respect to calcium bind- 
ing affinity (23, 67). Our results argue against radical hetero- 
geneity among the putative divalent cation sites. The divalent 
cation usage pattern was identical for each mutant and the 
relative order of effectiveness (Mn  2+  >  Mg  2+  >  Ca  2+,  on 
CS1/fibronectin; Mn  2+ >  Mg  2÷ =  Ca  2+, on VCAM-1) resem- 
bled that seen with wild-type a 4. 
Many integrin ligands contain an essential aspartic acid 
residue, and these have been hypothesized to directly coor- 
dinate with integrin divalent cations (7, 74). However, it is 
difficult to reconcile this model with our results showing that 
all three putative cation sites may be similar in terms of diva- 
lent cation usage and contribution to VLA-4 function, as it 
appears unlikely that three ligands would bind at once to the 
same integrin. Instead, the "missing" cation coordination in 
integrin EF-hand sites might be provided by water mole- 
cules, and/or by having a single amino acid supply two coor- 
dination sites, as is found for other EF-hand structures (68). 
Because there is only a  single putative EF-hand-type site 
within integrin/3 subunits (43), that is perhaps a better candi- 
date for direct ligand-cation contact. Consistent with this 
idea, an Asp to Tyr mutation at position 1 of the putative 133 
EF-hand caused complete loss of ligand binding function 
(43), and as Asp to Ala mutation at position 1 of the 131 EF- 
hand  site caused complete loss  of VLA-5  binding  either 
to fibronectin or to invasin (71). 
In conclusion, our results indicate that the three putative 
divalent cation sites within the VLA-4 a  chain contribute 
similarly to the function of the integrin, and support the con- 
cept that a  single integrin can adhere to multiple ligands, 
each regulated in a distinct manner. In future studies involv- 
ing  transgenlc  animals,  these  mutants  will  be  useful  for 
evaluating the in vivo functional consequences of expressing 
VLA-4 in which adhesion to CS1/fibronectin is diminished 
relative to adhesion to VCAM-1. 
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